October 23-27, 2011 Gatlinburg, TN page 8 of 45 17th Symposium on Separation Science and Technology for Energy Applications agents for human applications are being developed. Toward this goal, we are testing in vivo efficacy of Cuprimine and Syprine therapeutics, that are approved by the U.S. FDA to treat copper overload in Wilson Disease (a genetic defect in copper metabolism and transport), f...
